ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Jun 2023
Last Updated on 01 Jun 2023
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:

  • Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for the management of focal spasticity of the lower limbs associated with stroke in adults who:

    • have a score of 3 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment;
    • do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and
    • are concurrently receiving physiotherapy.

Funding status

Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023.

Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.

MAF assistance does not apply to Botox 200 U injection vial or other brands of botulinum toxin A.


Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults (Published 1 June 2023) PES Botulinum toxin A for treating adults with focal spasticity of the lower limbs associated with stroke (Published 1 June 2023)